CytoGenix to Present at 2007 International DNA Vaccines Conference in Spain

HOUSTON--(BUSINESS WIRE)--May 23, 2007 - CytoGenix, Inc. (CYGX.OB) announced today that Dr. Yin Chen, Chief Scientific Officer will present an update on preclinical animal data for DNA vaccines made using the Company's proprietary synDNA(TM) technology at the 2007 DNA Vaccines conference to be held in Malaga, Spain between May 23 and May 25.

Dr. Chen comments, "We have successfully conducted tests of synDNA(TM) based vaccines in mice, rabbits and non-human primates. The data to be presented will demonstrate the stimulation of the immune response comparing synDNA(TM) based vaccines to traditional plasmid DNA vaccines designed for the prevention of seasonal flu, HIV, smallpox and Hepatitis B. The tests indicate that the immune response triggered by synDNA(TM) vaccines is comparable to, and in some cases more effective than responses mediated by plasmid DNA. Data will also be shown demonstrating the effectiveness of a novel vaccine that protects against a highly virulent form of avian (bird) flu in animal challenge studies. These challenge experiments demonstrated that synDNA(TM) is just as effective as plasmid in mediating a protective immune response when the host is attacked by virulent viruses.

Malcolm Skolnick, CEO, states, "DNA vaccines have proven to be a potent means of providing protective immunity against viruses, bacteria and parasites in many species from fish to primates. Our animal tests demonstrate that DNA vaccines made with synDNA(TM) technology are not only effective in eliciting robust immune responses, but also provide protection against dangerous pathogens. Presentation of our data at the DNA vaccine conference is a great opportunity to showcase and discuss our work with other experts in this field including major pharmaceutical and biotech companies."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of therapeutic DNA inside the cell. CytoGenix currently holds 11 granted patents and about 49 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.

Contact

CytoGenix, Inc., Houston
Media Contact:
Pam Schertz, 713-789-0070

Posted: May 2007

View comments

Hide
(web1)